Alfa Cytology, a biomedical research support provider, has announced the enhancement of its radiopharmaceutical development service portfolio by integrating custom radiolabeling for antibody-drug conjugates (ADCs) and targeted radiopharmaceuticals with Radiopharmaceutical Physicochemical Characterization CRO services. This move aims to offer comprehensive research and development support to biotechnology companies, pharmaceutical firms, and academic institutions.
Radiopharmaceuticals have emerged as a critical area in precision medicine, with growing applications in cancer diagnosis and targeted therapy. Research projects increasingly rely on radiolabeling technologies for pharmacokinetic studies, biodistribution analysis, and molecular imaging. Concurrently, the rapid progress in ADCs, peptide therapeutics, and targeted small molecules has intensified the demand for advanced radiopharmaceutical development capabilities.
However, successful radiolabeling alone does not ensure the viability of a candidate. Key attributes such as radiochemical purity, stability, lipophilicity, and target-binding capability require thorough evaluation. Alfa Cytology addresses this need by integrating radiolabeling and physicochemical characterization, enabling researchers to obtain high-quality radiolabeled products while systematically assessing critical quality attributes.
In radiolabeling, Alfa Cytology offers custom services for antibodies, ADCs, peptide therapeutics, small molecules, and other targeted compounds, supporting various radionuclides for diagnostic and therapeutic use. These services are applicable to pharmacokinetic studies, biodistribution analysis, molecular imaging, and radiopharmaceutical development. The company's physicochemical characterization services cover analysis of radiochemical purity, stability, lipophilicity (LogP/LogD), and immunoreactivity, helping research teams evaluate candidate properties and generate reliable data.
A spokesperson for Alfa Cytology stated, "The demand for high-quality radiolabeling and physicochemical characterization data continues to grow as radiopharmaceutical development advances. By integrating our technical capabilities, we aim to provide customers with more efficient research support and help advance the development of innovative radiopharmaceuticals and targeted therapies."
For more information on Alfa Cytology's custom radiolabeling for ADCs and targeted radiopharmaceuticals and Radiopharmaceutical Physicochemical Characterization CRO services, visit their website.
